Recursion Pharmaceuticals, Inc. (RXRX) Earnings Call Transcripts
Recursion Pharmaceuticals, Inc.'s Latest Earnings Call - June 9, 2026
Recursion Pharmaceuticals, Inc. reported a strong quarter for Q2 2026, with notable advancements in its clinical pipeline and strategic partnerships. The company generated $500 million from partnerships, primarily with Roche and Sanofi, and emphasized its AI-driven approach to drug discovery, which is expected to enhance efficiency and reduce costs. Management signaled a robust pipeline with five clinical programs and upcoming data releases, particularly for its lead program in familial adenomatous polyposis (FAP), which is in discussions with the FDA for trial design. The cash runway has been extended to early 2028, indicating solid financial management amidst ongoing operational efficiencies.
Reported metrics
| Metric | Value |
|---|---|
| Partnership Revenue | $500M (positive) |
| Cash Runway | Early 2028 (positive) |
| Cost Reduction | 35% (positive) |
| Clinical Programs | 5 (positive) |
| FDA Engagement | Ongoing (positive) |
| AI Integration | AI-native platform (positive) |
Guidance from management
Management has not provided specific revenue or earnings guidance but indicated a strong focus on advancing their clinical pipeline and maintaining operational efficiencies to extend their cash runway into early 2028.
What management said
I mean anything in cancer is a combo opportunity, just how it's used clinically. From a mechanistic perspective, if you had a genomically instable cancer, absolutely, you should see some activity. So what we tried to do is it wasn't a biomarker targeted Phase I/II. It was a biomarker enriched. So what we went is we went after indications that have a higher prevalence of genomically instable cancers. And so we do want...
What analysts pressed on
Analysts raised questions about the competitive landscape in AI-driven drug development and the potential risks associated with the clinical trial outcomes. There is concern regarding how Recursion will differentiate itself from other biotech firms leveraging AI, as well as the sustainability of its partnership revenue model in the long term.
Main topics on the call
- Partnership Revenue Generation — Recursion has secured over $500 million from partnerships, primarily with Roche and Sanofi, which management described as 'high-value, high NPV programs.' This revenue stream is crucial for maintaining operational stabil...
- Pipeline Progress and Data Releases — Management highlighted that they have five clinical programs with data expected within the next 12 months, particularly focusing on the FAP program. They stated, 'we're currently in FDA discussions on the registrational ...
- Cost Management and Efficiency — Recursion has successfully reduced operational costs by 35% since the merger with Exscientia, which was described as 'impact modeling' rather than cost cutting. This approach has allowed the company to maintain a robust ...
- AI-Driven Drug Development — The company emphasized its AI-native platform, stating, 'we actually look at every single problem, and we say, is there a better way that we can do it using data, using AI.' This positions Recursion as a leader in integr...
Read the full Recursion Pharmaceuticals, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 25 calls on record spanning August 8, 2024 to August 11, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 25 Recursion Pharmaceuticals, Inc. earnings call transcripts on record, spanning August 8, 2024 to August 11, 2026. Based on this history, Recursion Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated August 11, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RXRX
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 25
- First call
- August 8, 2024
- Most recent
- August 11, 2026
- Reporting cadence
- quarterly